Evidence overview
Vitamin D3
Vitamin D3 is among the most-studied vitamins, with research spanning bone health, fracture risk, immune function, cardiovascular outcomes, cancer, and mood. The evidence base is unusually large and unusually mixed, with baseline status the single biggest modifier of who responds to supplementation. A coverage map is the most honest way to read what is and is not settled.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Prohormone hydroxylated in the liver to 25-hydroxyvitamin D (the primary status marker) and activated...
Study coverage
Study coverage by goal
PubMed counts for Vitamin D3 grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Vitamin D3.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Vitamin D3 (cholecalciferol) is one of the most-researched vitamins in modern supplement science, with a literature spanning bone density and fracture prevention, cardiovascular and cancer outcomes (the past decade's megatrials), immune function, mood, and pregnancy. The body activates D3 through liver and kidney hydroxylation into calcitriol, which binds vitamin D receptors throughout the body to regulate calcium and modulate gene expression - which is part of why the supplement is studied across such a wide range of outcomes. D3 has largely displaced D2 (ergocalciferol) in supplement trials on bioavailability grounds and is the form used in nearly all major modern studies.
The outcome dimensions covered most heavily are bone density, falls, and fracture risk in older adults; cardiovascular and cancer outcomes in the past decade of megatrials; immune-related outcomes (especially in the post-2020 wave); and mood/depression. Pediatric rickets prevention anchors the foundational end of the literature. Newer growth areas include autoimmune conditions, pregnancy outcomes, and respiratory infection prevention.
Demographically, postmenopausal women dominated the bone-density era and still feature heavily in the long-running trials. Megatrials enrolling broader adult populations have widened the picture, but the single biggest modifier of who responds to supplementation is baseline vitamin D status - measured as serum 25-hydroxyvitamin D - which trials use both as an enrollment criterion and, in many cases, as the primary endpoint. Trials enrolling already-replete populations typically show smaller effects than trials enrolling deficient populations, which is part of why pooled effect estimates can mask meaningful subgroup signals.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Vitamin D3 is generally well-tolerated at typical supplement doses. Toxicity is rare but possible at sustained very high intakes, with hypercalcemia as the principal warning sign. The IOM tolerable upper limit for adults is 4,000 IU/day; some endocrine societies argue for higher tolerable ranges in selected contexts. Drug interactions include thiazide diuretics (additive calcium retention), corticosteroids (impaired vitamin D metabolism), and orlistat or bile-acid sequestrants (reduced fat-soluble absorption). Conditions that warrant clinician guidance before supplementing include primary hyperparathyroidism, granulomatous diseases such as sarcoidosis, and chronic kidney disease, all of which can alter vitamin D handling. Source guidance includes the IOM Dietary Reference Intakes report and the Endocrine Society clinical practice guidelines.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
The Endocrine Society practice guideline on vitamin D for disease prevention. Practice guidelines from major endocrinology bodies define the canonical scientific position on vitamin D supplementation; this 2024 update is the document the field anchors on for current recommendations.
View on PubMedEstablishes the field reference for the D2-versus-D3 question, which is the most-asked formulation choice for consumers. The methodological depth (including BMI modifier analysis) sets the bar for how this question is now framed in the literature.
View on PubMedThe foundational synthesis on vitamin D3 plus calcium for fracture prevention in older adults - the indication with the longest-running evidence base and the one most often cited in clinical contexts.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page covers vitamin D3 at the general literature level. It does not address whether you are personally deficient, sufficient, or replete (which requires a 25(OH)D blood test), what dose your particular status calls for, whether your latitude and habitual sun exposure already cover your needs, or how vitamin D fits with the medications and other supplements you take. Whether you actually benefit from supplementation depends heavily on baseline status, which is one of the most consequential modifiers in this literature and the reason a personalized report is more informative than a population-level summary.
Personalized to you
Get a personalized Vitamin D3 report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Vitamin D3 materially updates. No account required.